Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 Annual Meeting of the Endocrine Society (ENDO)

March 4, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search